$2-M investment boosts thromboembolism research
var addthis_config = {
data_track_clickback: true
}
At a special event this week, St. Joseph's Healthcare Foundation and LEO Pharma Inc. announced a new research chair partnership supporting thromboembolism initiatives at McMaster University and St. Joseph's Healthcare Hamilton.
A $2-million investment in basic science research from the Canadian division of the globally renowned research-based pharmaceutical company will result in the establishment of the LEO Pharma Chair in Thromboembolism at McMaster University. Thromboembolism is both thrombosis – the formation of a blood clot inside a blood vessel – and its main complication, embolism, which occurs when a clot migrates to another part of the body and causes a blockage.
“At LEO Pharma we are committed to research and development as the means of helping patients fight serious illnesses. We are proud to support thromboembolism initiatives at St. Joseph's Healthcare Hamilton (SJHH) and McMaster University,” said Ken Jones, president and CEO, LEO Pharma Inc.
John Kelton, dean and vice-president of the Faculty of Health Sciences, said the University has been a world-leading centre for thromboembolism and SJHH has played an active role in this research for more than 40 years.
“This generous gift of LEO Pharma Inc. and our partnership with St. Joseph's will help create innovations that could lead to better treatments,” he said.
“LEO Pharma's investment and the establishment of the Chair in Thromboembolism is born out of many people working together in the spirit of collaboration and partnership and it will only strengthen our research initiatives at St. Joseph's and McMaster University,” said Sera Filice-Armenio, president and CEO of St. Joseph's Healthcare Foundation.
McMaster University's Division of Hematology and Thromboembolism includes the St. Joseph's Thromboembolism Research Centre, located across from the Charlton Avenue hospital. The division has an active research program, and has achieved worldwide recognition for its work in thrombosis and hemostasis, platelet physiology and function, blood transfusion therapy, the molecular biology of thalassemia and clinical trials in malignant hematological diseases.
“It is most exciting to see one of the premier research and clinical divisions of both St. Joseph's Healthcare Hamilton and McMaster University embark upon a new frontier, thanks in part to the LEO Pharma Chair in Thromboembolism. This is research that goes from bench to bedside and ultimately benefits patients in our community and well beyond,” said David Higgins, president of St. Joseph's Healthcare Hamilton.
A formal announcement of the chair holder will be made public in the summer.
Stay connected
